These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 35356961)

  • 1. Self-assembled di- and tripeptide gels for the passive entrapment and pH-responsive, sustained release of an antidiabetic drug, glimepiride.
    Halder M; Bhatia Y; Singh Y
    Biomater Sci; 2022 May; 10(9):2248-2262. PubMed ID: 35356961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Glimepiride--an oral antidiabetic agent].
    Becić F; Kapić E; Becić E
    Med Arh; 2003; 57(2):125-7. PubMed ID: 12822388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE; Matthews DR
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Glimepiride versus Saxagliptin on β-Cell Function and Hypoglycemia: A Post Hoc Analysis in Older Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
    Perl S; Cook W; Wei C; Ohman P; Hirshberg B
    Clin Ther; 2016 Dec; 38(12):2578-2588. PubMed ID: 27823868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-Assembled Fmoc-Arg-Phe-Phe Peptide Gels with Highly Potent Bactericidal Activities.
    Chauhan N; Singh Y
    ACS Biomater Sci Eng; 2020 Oct; 6(10):5507-5518. PubMed ID: 33320569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Counterregulatory responses to hypoglycemia differ between glimepiride and glyburide in non diabetic individuals.
    Joy NG; Tate DB; Davis SN
    Metabolism; 2015 Jun; 64(6):729-37. PubMed ID: 25765720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electrostatic and aromatic interaction-directed supramolecular self-assembly of a designed Fmoc-tripeptide into helical nanoribbons.
    Xie Y; Wang X; Huang R; Qi W; Wang Y; Su R; He Z
    Langmuir; 2015 Mar; 31(9):2885-94. PubMed ID: 25694059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial.
    Fujimoto K; Shibayama Y; Yamaguchi E; Honjo S; Hamasaki A; Hamamoto Y
    J Diabetes; 2018 Aug; 10(8):675-682. PubMed ID: 29493100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glimepiride. A review of its use in the management of type 2 diabetes mellitus.
    Langtry HD; Balfour JA
    Drugs; 1998 Apr; 55(4):563-84. PubMed ID: 9561345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of glimepiride and glyburide on glucose counterregulation and recovery from hypoglycemia.
    Szoke E; Gosmanov NR; Sinkin JC; Nihalani A; Fender AB; Cryer PE; Meyer C; Gerich JE
    Metabolism; 2006 Jan; 55(1):78-83. PubMed ID: 16324923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic comparison of a new sustained-release formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized, 2-sequence, 2-period, 2-treatment crossover study.
    Shin KH; Kim SE; Yoon SH; Cho JY; Jang IJ; Shin SG; Yu KS
    Clin Ther; 2011 Nov; 33(11):1809-18. PubMed ID: 22036245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience.
    Massi-Benedetti M
    Clin Ther; 2003 Mar; 25(3):799-816. PubMed ID: 12852703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride.
    Korytkowski MT
    Pharmacotherapy; 2004 May; 24(5):606-20. PubMed ID: 15162895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broad-Spectrum Antibacterial Activity of Proteolytically Stable Self-Assembled αγ-Hybrid Peptide Gels.
    Malhotra K; Shankar S; Rai R; Singh Y
    Biomacromolecules; 2018 Mar; 19(3):782-792. PubMed ID: 29384665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Glimepiride (Amaryl): a review of its pharmacological and clinical profile].
    Bando K; Yamada Y
    Nihon Yakurigaku Zasshi; 2001 Jul; 118(1):59-67. PubMed ID: 11496829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Glimepiride in daily practice].
    Jasik M
    Przegl Lek; 2003; 60(6):409-12. PubMed ID: 14974179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Injectable self-assembled peptide hydrogels for glucose-mediated insulin delivery.
    Fu M; Zhang C; Dai Y; Li X; Pan M; Huang W; Qian H; Ge L
    Biomater Sci; 2018 May; 6(6):1480-1491. PubMed ID: 29623975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel-loaded pH responsive hydrogel based on self-assembled peptides for tumor targeting.
    Raza F; Zhu Y; Chen L; You X; Zhang J; Khan A; Khan MW; Hasnat M; Zafar H; Wu J; Ge L
    Biomater Sci; 2019 Apr; 7(5):2023-2036. PubMed ID: 30839983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormonal counterregulation and consecutive glimepiride serum concentrations during severe hypoglycaemia associated with glimepiride therapy.
    Holstein A; Plaschke A; Hammer C; Ptak M; Kuhn J; Kratzsch C; Diekmann J; Kleesiek K; Maurer HH; Egberts EH
    Eur J Clin Pharmacol; 2003 Dec; 59(10):747-54. PubMed ID: 14634699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients.
    Rosenkranz B
    Horm Metab Res; 1996 Sep; 28(9):434-9. PubMed ID: 8911979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.